Biomarkers in HCV Infection
作者： Seung Ha Park , Chang Seok Bang , Dong Joon Kim
DOI: 10.1016/BS.ACC.2015.03.001
关键词:
摘要: Liver-related biomarkers have been developed and validated mainly in patients with chronic hepatitis C for the prediction of liver fibrosis or cirrhosis, which is a final pathway injury. They are noninvasive, traceable, easy-to-use. Biomarkers provide implications related to screening, diagnosis, treatment, prognosis hepatitis. For improvement performance coverage, biomarker panels, imaging biomarkers, even genetic developed. With advancement genomics proteomics, earlier more precise expected near future. In this review, multiple panels estimation degree C, screening diagnosis treatment complications future perspectives will be summarized.
elsevier.com
sci-hub.se 参考文章(319)
Cynthia S. Santillan, An Tang, Irene Cruite, Amol Shah, Claude B. Sirlin, Understanding LI-RADS Magnetic Resonance Imaging Clinics of North America. ,vol. 22, pp. 337- 352 ,(2014) , 10.1016/J.MRIC.2014.04.007
Douglas B. McGill, Jorge Rakela, Alan R. Zinsmeister, Beverly J. Ott, A 21-year experience with major hemorrhage after percutaneous liver biopsy Gastroenterology. ,vol. 99, pp. 1396- 1400 ,(1990) , 10.1016/0016-5085(90)91167-5
Naoki Fujita, Mamoru Nakanishi, Jun Mukai, Yuuji Naito, Takafumi Ichida, Masahiko Kaito, Toshikazu Yoshikawa, Yoshiyuki Takei, Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. Molecular Medicine. ,vol. 17, pp. 70- 78 ,(2011) , 10.2119/MOLMED.2010.00124
H James Hnatyszyn, Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes Antiviral Therapy. ,vol. 10, pp. 1- 11 ,(2005)
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
K.-H. Meyer zum Büschenfelde, G. Gerken, M. Manns, Hepatitis C virus (HCV) and autoimmune liver diseases Archives of virology. Supplementum. ,vol. 4, pp. 201- 204 ,(1992) , 10.1007/978-3-7091-5633-9_42
Keun Na, Seul-Ki Jeong, Min Jung Lee, Sang Yun Cho, Sun A Kim, Min-Ji Lee, Si Young Song, Hoguen Kim, Kyung Sik Kim, Hyun Woong Lee, Young-Ki Paik, Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. International Journal of Cancer. ,vol. 133, pp. 408- 415 ,(2013) , 10.1002/IJC.28020
A. K. P. Lim, N. Patel, R. J. Eckersley, J. F. L. Cobbold, M. M. E. Crossey, D. O. Cosgrove, R. D. Goldin, H. C. Thomas, S. D. Taylor-Robinson, Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C Journal of Viral Hepatitis. ,vol. 17, pp. 778- 783 ,(2010) , 10.1111/J.1365-2893.2009.01234.X
Zheng-Feng Yin, Jia-Mei Yang, Yan-Ming Zhou, Bin Li, Tong Kan, Wen Xu, Bin Wang, Feng Xu, Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary & Pancreatic Diseases International. ,vol. 9, pp. 33- 37 ,(2010)
Akinobu Takaki, Manfred Wiese, Geert Maertens, Erik Depla, Ulrike Seifert, Anke Liebetrau, Jeffery L. Miller, Michael P. Manns, Barbara Rehermann, Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C Nature Medicine. ,vol. 6, pp. 578- 582 ,(2000) , 10.1038/75063